Basic Science Researcher
Dr. Stewart Cooper
Improving the prevention and treatment of hepatitis B, hepatitis C, and other liver diseases
Dr. Cooper studies molecular and genetic changes underlying liver diseases including hepatitis B and C, and he uses genomic and proteomic approaches to uncover new therapeutic targets for the hepatitis virus.
Current research in the Cooper lab includes investigations of how natural killer cells, T cells, and hybrid natural killer T cells may interact to clear hepatitis C, and how related sets of genes influence immune response.
Dr. Cooper directs the Kalmanovitz Liver Immunology Laboratory at CPMC, and leads translational research to identify immunological influences on disease outcomes in patients with hepatitis C (including those undergoing liver transplantation). Under Dr. Cooper’s leadership, validated biomarkers for liver and biliary diseases will be used to personalize treatment and help predict an individual’s response to therapy.
Dr. Cooper received his M.D. at Welsh National School of Medicine in Cardiff, Wales (UK). He completed residency training at the University Hospital of Wales and a fellowship in gastroenterology at Stanford University School of Medicine in Palo Alto, California.
Publications by Steward Cooper Opens new windowin PubMed.
Representative publications include:
- Publicover J, Gaggar A, Nishimura S, Van Horn CM, Goodsell A, Muench MO, Reinhardt RL, van Rooijen N, Wakil AE, Peters M, Cyster JG, Erle DJ, Rosenthal P, Cooper S, Baron JL. Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B. J Clin Invest 2013;123(9):3728-39. Epub Aug 8, 2013.
- Singh KM, Phung YT, Kohla MS, Lan BY, Chan S, Suen DL, Murad S, Rheault S, Davidson P, Evans J, Singh M, Dohil S, Osorio RW, Wakil AE, Page K, Feng S, Cooper SL. KIR genotypic diversity can track ancestries in heterogeneous populations: a potential confounder for disease association studies. Immunogenetics 2012;64(2):97-109.
- Gish RG, Cooper SL. Hepatitis B in the Greater San Francisco Bay Area: an integrated programme to respond to a diverse local epidemic. J Viral Hepat. 2011 Apr;18(4):e40-51.
- Bernardin F, Stramer SL, Rehermann B, Page-Shafer K, Cooper S, Bangsberg DR, Hahn J, Tobler L, Busch M, Delwart E. High levels of subgenomic HCV plasma RNA in immunosilent infections.Virology. 2007 Sep 1;365(2):446-56. Epub 2007 May 9.
- Tobler LH, Stramer SL, Chien DY, Lin S, Arcangel P, Phelps BH, Cooper SL, Busch MP. Antibodies to a novel antigen in acute hepatitis C virus infections. Vox Sang. 2007 Jan;92(1):1-7.